Eisai nabs quick FDA blessing for cancer blockbuster hopeful Lenvima

Carly Helfand Eisai grabbed an early green light on Friday from U.S. regulators for thyroid cancer drug Lenvima, meaning the Japanese pharma can now get an earlier-than-expected start ...

Eisai wins an early FDA nod for its self-described cancer blockbuster

Damian Garde Eisai is counting on its new cancer drug to eventually bring in more than $ 1 billion a year, and now, thanks to an early FDA approval, the Japanese drugmaker has a head ...

Synta cuts another 20% of staff and rallies around its cancer drug

Damian Garde Synta Pharmaceuticals is again slashing its payroll, cutting costs across the board as it presses ahead with ganetespib, a long-delayed cancer treatment. FierceBiotech ...

Singapore to detail trial of MicroVAX novel cancer vaccine

EJ Lane The National Cancer Centre of Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration ...

Oncothyreon is going it alone with Array’s former breast cancer contender

Damian Garde Moving on from the slow demise of its Merck KGaA-partnered cancer vaccine, Seattle's Oncothyreon has bought out co-developer Array BioPharma, acquiring exclusive rights ...

Novartis’ bid to widen Afinitor’s breast cancer reach falls short in PhIII

Carly Helfand Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod ...

Roche’s Avastin wins FDA green light in ovarian cancer

Carly Helfand Roche's Avastin is now two-for-two on converting recent FDA priority review designations into label expansions. Just three months after the cancer giant nabbed the ...

Blueprint Medicines banks $50M for its personalized take on cancer

Damian Garde Third Rock Ventures startup Blueprint Medicines has hauled in a $ 50 million C round, cash that'll see its way through clinical trials and keep its promising platform ...

Threshold shares surge as PhIII cancer program enters FDA’s fast track

John Carroll Shares of Threshold Pharmaceuticals jumped about 10% this morning on news that the FDA is granting fast-track status to TH-302, the company’s sole therapy now in ...

Tolero wraps up a $22.4M round to support its cancer contender

Damian Garde Tolero Pharmaceuticals has pocketed a second tranche of its Series B funding round, netting $ 22.4 million in total as it prepares to take its expirimental marrow cancer ...

GlaxoSmithKline’s effort to relaunch cancer R&D faces skepticism

John Carroll GlaxoSmithKline made a high-profile decision to exit the cancer drug field in its recent deal with Novartis, but as Reuters reports, a band of specialists inside GSK still ...

FDA advisers spurn Novartis’ blood cancer drug, putting approval in doubt

Damian Garde Novartis' new multiple myeloma is treatment too risky to be approved, a group of FDA advisers voted, dealing a blow to the drugmaker and its hopes of launching the ...
Page 5 of 23« First...34567...1020...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS